Phaseline

Companies › Fujian Haixi Pharmaceuticals

Fujian Haixi Pharmaceuticals: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Ophthalmology; next expected readout Jul 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HX9428–Phase 1Wet Age-related Macular Degeneration (AMD)Jul 2028
C019199–Phase 1Solid Tumor–
Sintilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 1Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06220318C019199Phase 1Solid TumorOncologyAug 2026
NCT06220318SintilimabPhase 1Solid TumorOncologyAug 2026
NCT07185841HX9428Phase 1Wet Age-related Macular Degeneration (AMD)OphthalmologyJul 2028

Targets

PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.